company background image
A145

Hugel KOSDAQ:A145020 Stock Report

Last Price

₩134.20k

Market Cap

₩1.6t

7D

5.7%

1Y

-39.6%

Updated

14 Aug, 2022

Data

Company Financials +
A145020 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance1/6
Financial Health5/6
Dividends0/6

A145020 Stock Overview

Hugel, Inc. operates as a biopharmaceutical company in South Korea and internationally.

Rewards

Trading at 26.2% below our estimate of its fair value

Earnings are forecast to grow 23.22% per year

Risk Analysis

No risks detected for A145020 from our risk checks.

Hugel Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Hugel
Historical stock prices
Current Share Price₩134,200.00
52 Week High₩231,900.00
52 Week Low₩100,900.00
Beta0.81
1 Month Change17.51%
3 Month Change15.29%
1 Year Change-39.63%
3 Year Change16.29%
5 Year Change-26.83%
Change since IPO139.22%

Recent News & Updates

Shareholder Returns

A145020KR BiotechsKR Market
7D5.7%1.0%1.2%
1Y-39.6%-37.2%-20.1%

Return vs Industry: A145020 underperformed the KR Biotechs industry which returned -37.2% over the past year.

Return vs Market: A145020 underperformed the KR Market which returned -20.1% over the past year.

Price Volatility

Is A145020's price volatile compared to industry and market?
A145020 volatility
A145020 Average Weekly Movement6.0%
Biotechs Industry Average Movement8.2%
Market Average Movement6.4%
10% most volatile stocks in KR Market10.9%
10% least volatile stocks in KR Market3.9%

Stable Share Price: A145020 is not significantly more volatile than the rest of KR stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: A145020's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2001456Ji-hoon Sohnhttps://www.hugel.co.kr

Hugel, Inc. operates as a biopharmaceutical company in South Korea and internationally. It offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years of age, as well as improvement of external angles of secondary ideals related to orbicularis oculi muscle activity in adults aged between 19 and 65 under the Botulax, Regenox, Zentox, Reage, Magnion, Hugel Toxin, Juvenlife, Botulim, and Botoshot brands. The company also provides hyaluronic acid filler under the Dermalax, Hyalsense, Revigance, and The Chaeum brand names; cosmetics under the Wellage brand; and medical devices.

Hugel Fundamentals Summary

How do Hugel's earnings and revenue compare to its market cap?
A145020 fundamental statistics
Market Cap₩1.59t
Earnings (TTM)₩54.08b
Revenue (TTM)₩246.23b

29.4x

P/E Ratio

6.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
A145020 income statement (TTM)
Revenue₩246.23b
Cost of Revenue₩65.75b
Gross Profit₩180.48b
Other Expenses₩126.40b
Earnings₩54.08b

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)4.57k
Gross Margin73.30%
Net Profit Margin21.96%
Debt/Equity Ratio11.4%

How did A145020 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is A145020 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A145020?

Other financial metrics that can be useful for relative valuation.

A145020 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.8x
Enterprise Value/EBITDA11x
PEG Ratio1.3x

Price to Earnings Ratio vs Peers

How does A145020's PE Ratio compare to its peers?

A145020 PE Ratio vs Peers
The above table shows the PE ratio for A145020 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.2x
A006280 Green Cross
17.1x11.2%₩2.0t
A005250 Green Cross Holdings
23.6xn/a₩925.6b
A144510 GC Cell
19.1xn/a₩974.6b
A290650 L&C Bio
48.7xn/a₩642.0b
A145020 Hugel
29.4x23.2%₩1.6t

Price-To-Earnings vs Peers: A145020 is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the peer average (27.2x).


Price to Earnings Ratio vs Industry

How does A145020's PE Ratio compare vs other companies in the KR Biotechs Industry?

Price-To-Earnings vs Industry: A145020 is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the KR Biotechs industry average (26.8x)


Price to Earnings Ratio vs Fair Ratio

What is A145020's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A145020 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio29.4x
Fair PE Ratio28.3x

Price-To-Earnings vs Fair Ratio: A145020 is expensive based on its Price-To-Earnings Ratio (29.4x) compared to the estimated Fair Price-To-Earnings Ratio (28.3x).


Share Price vs Fair Value

What is the Fair Price of A145020 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: A145020 (₩134200) is trading below our estimate of fair value (₩181837.49)

Significantly Below Fair Value: A145020 is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Hugel forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


23.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: A145020's forecast earnings growth (23.2% per year) is above the savings rate (3.6%).

Earnings vs Market: A145020's earnings (23.2% per year) are forecast to grow faster than the KR market (16.4% per year).

High Growth Earnings: A145020's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: A145020's revenue (16.9% per year) is forecast to grow faster than the KR market (9.9% per year).

High Growth Revenue: A145020's revenue (16.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: A145020's Return on Equity is forecast to be low in 3 years time (10%).


Discover growth companies

Past Performance

How has Hugel performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-6.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: A145020 has high quality earnings.

Growing Profit Margin: A145020's current net profit margins (22%) are lower than last year (23.4%).


Past Earnings Growth Analysis

Earnings Trend: A145020's earnings have declined by 6.9% per year over the past 5 years.

Accelerating Growth: A145020's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A145020 had negative earnings growth (-1%) over the past year, making it difficult to compare to the Biotechs industry average (16.8%).


Return on Equity

High ROE: A145020's Return on Equity (6.8%) is considered low.


Discover strong past performing companies

Financial Health

How is Hugel's financial position?

Financial Health Score

5/6

Financial Health Score 5/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: A145020's short term assets (₩617.4B) exceed its short term liabilities (₩49.1B).

Long Term Liabilities: A145020's short term assets (₩617.4B) exceed its long term liabilities (₩129.3B).


Debt to Equity History and Analysis

Debt Level: A145020 has more cash than its total debt.

Reducing Debt: A145020's debt to equity ratio has increased from 0.1% to 11.4% over the past 5 years.

Debt Coverage: A145020's debt is well covered by operating cash flow (101.8%).

Interest Coverage: A145020 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Discover healthy companies

Dividend

What is Hugel current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate A145020's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate A145020's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if A145020's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if A145020's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as A145020 has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

4.6yrs

Average management tenure


CEO

Ji-hoon Sohn

4.58yrs

Tenure

Mr. Ji-hoon Sohn serves as Co-Chair of the Board of Directors at Hugel, Inc. and has been its Chief Executive Officer since 2018 and is its Director since March 2018. He served as Chief Executive Officer a...


Leadership Team

Experienced Management: A145020's management team is considered experienced (4.6 years average tenure).


Board Members

Experienced Board: A145020's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Hugel, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Hugel, Inc.
  • Ticker: A145020
  • Exchange: KOSDAQ
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₩1.590t
  • Shares outstanding: 11.85m
  • Website: https://www.hugel.co.kr

Number of Employees


Location

  • Hugel, Inc.
  • 61-20, Sinbuk-ro
  • Sinbuk-eup
  • Chuncheon-si
  • Gangwon-do
  • 24206
  • South Korea

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/14 00:00
End of Day Share Price2022/08/12 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.